Tridem begins phase Ib trial of Parkinson’s disease vaccine
October 13, 2026Cardiology, Neurology, Parkinson's disease, Vaccine, clinical trial
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, an intradermal therapeutic vaccine targeting …
Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
October 13, 2026Cardiology, Cleanroom, Diabetes, Haematology, Neurology, Rare Diseases, cell therapies, manufacturing and production, small molecules
Bio-Techne has opened a new facility in Bristol manufacturing Good Manufacturing Practice (GMP)-grade small molecules for cell therapy developers. The …
Trio become latest Symbiosis commercial additions
October 12, 2026CDMO, Devices, Diagnostics, Immunology, clinical trials, pharmaceutical markets
Symbiosis Pharmaceutical Services has further strengthened its commercial team with three new appointments. Payal Roychoudhury and JoaquÃn Pérez Fornieles join …
UK immunoglobulin supply faces growing pressure, report warns
October 12, 2026Manufacturing and Production Critical supplies, Immunology, NHS Blood and Transplant, Neurology, procurement
The UK may face increasing pressure to secure long-term supplies of immunoglobulin (Ig), with rising demand and heavy reliance on …
How will biomarker-led diagnostics reshape respiratory medicine?
October 11, 2026Asthma & COPD, COPD, Chronic Diseases, Diagnostics, biomarkers, clinical trial
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed through symptoms, lung function and …
Five Facts about COPD
October 11, 2026Medical Communications Asthma & COPD, COPD, Five Facts, HRT, Smoking Cessation, chronic bronchitis, emphysema, smoking
1 Chronic obstructive pulmonary disease is a group of progressive lung conditions, principally emphysema and chronic bronchitis, that restrict airflow …
“That gap between innovation and delivery was what stood out to me most”
October 11, 2026Drug Delivery Systems, Drug Safety, Marketing, Medical Communications, Regulatory Affairs AI governance, Asthma & COPD, Chronic Diseases, Devices, Diagnostics, Hospital Management, NHS, drug delivery, healthcare solutions, pharmaceutical technology
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and putting the patient at the …
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
October 11, 2026Licenses/Quality Standards, Marketing, Sales & Marketing Training AI, Devices, Diagnostics, Hospital Management, Pharmacy, biopharma, medical adoption, pharmaceutical
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between sales reps and physicians or …
Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
October 11, 2026Chronic Diseases, NHS, Oncology, cardiovascular disease, survey
People in their forties account for almost three-quarters of those who do not attend NHS Health Checks, highlighting the challenge …
Excellence in Healthcare Partnership Awards – A Collaborative Working Project Between Sanofi and The University Hospital Birmingham Severe Asthma Team
October 11, 2026Data Management, Medical Communications, Medical Education, Patient Awareness Programmes, Quality Assurance, Training Asthma & COPD, Chronic Diseases, EHP Awards, HCPs, Sanofi
Launched in February 2026 by PMGroup Worldwide Ltd and Visions4Health, the Excellence in Healthcare Partnerships (EHP) Awards recognise outstanding collaborations …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
October 8, 2026NICE, Oncology, drug recommendation, drug regulation
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for previously untreated adults with multiple …
AstraZeneca’s Trixeo approved in EU for asthma
October 8, 2026Asthma & COPD, AstraZeneca, EU
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a maintenance treatment for asthma in …
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
October 7, 2026Rheumatology, clinical testing, immunology, rheumatoid arthritis
Amplio Pharma has reported phase 1b results for NovoBioJect, an investigational combination of low-dose methotrexate (MTX) and novobiocin being developed …
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
October 6, 2026Diabetes, GLP-1, Obesity, diabetes, obesity, phase 3 trial
Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in people with obesity or overweight …
ESTEVE CDMO adds $17.5m to Illinois expansion
October 6, 2026Clinical trials supplies & documentation logistics, Logistics & Distribution, Manufacturing and Production, Warehousing & distribution API manufacture, Corporate, Pharmacy, investment, laboratory, pharma production
ESTEVE CDMO is investing a further $17.5m to expand capacity and containment capabilities at its Morton Grove facility in Illinois, …
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
October 4, 2026Asthma & COPD, COPD, asthma, clinical trials, monoclonal antibodies
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two phase 3 trials, cutting exacerbation …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
October 4, 2026Biopharmaceuticals, Pharmacy, cell culture, manufacturing
Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for biopharmaceutical manufacturing. Under the agreement, …
CeramTec expands German production capacity for orthopaedic ceramics
October 2, 2026CeramTec, Germany, Marktredwitz, orthopaedic ceramics
CeramTec has opened a 12,000m² extension at its Marktredwitz site in Germany, adding around 5,000m² of production space for ceramic …
Migraine annual economic and quality-of-life burden in UK
October 1, 2026AbbVie UK, Health Innovation Manchester, migraine, quality-of-life burden
Migraine affects an estimated 280,000 people across Greater Manchester and creates an annual economic and quality-of-life burden of around £870m, …
bit.bio expands human heart cell portfolio through myriamed partnership
September 30, 2026Biotechnology, bit.bio, drug discovery, myriamed, safety testing
bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem cell (iPSC)-derived cardiomyocytes for drug …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
